The production of sIL-2Rα by lymphoma cells suggests that supplementation with IL-2 may be a valid treatment strategy; however, the dual role of IL-2 in expanding both cytotoxic effector cells as well as Tregs complicates its efficacy as a therapy on its own. The gene discussed is IL2; the disease is lymphoma.